Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[11C]SP203 is a carbon-11 labeled radiopharmaceutical developed as a positron emission tomography (PET) radioligand for the high-affinity and selective imaging of metabotropic glutamate receptor 5 (mGluR5) in the brain. It is the short-lived carbon-11 analog (t1/2 ≈ 20.4 min) of the fluorine-18 labeled ligand [18F]SP203, designed to facilitate multiple scanning sessions in the same subject within a single day. Chemically, it is a thiazole derivative where the carbon-11 label is typically incorporated into the nitrile group. The ligand binds with high specificity to mGluR5, a G-protein coupled receptor implicated in various neurological and psychiatric conditions, including Fragile X syndrome, depression, and Parkinson's disease. While preclinical studies in rhesus monkeys showed high brain uptake followed by rapid metabolism in blood, studies in humans have supported its utility as a tool for quantifying mGluR5 density and occupancy in the central nervous system.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [11C]SP203.